Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.52 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.48 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1502287 | 1.00 | DRD4 (0.52) | DRD4DRD2DRD3ALDH1A1EPHX2 | |
| SCHEMBL13853942 | 1.00 | DRD4 (0.52) | DRD4DRD2DRD3ALDH1A1EPHX2 | |
| SCHEMBL12046265 | 0.88 | CCR3 (0.61) | DRD4DRD3ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL31165348 | 0.88 | NPFFR1 (0.49) | DRD2ALDH1A1NPFFR1NPFFR2 | |
| SCHEMBL4178261 | 0.85 | MAPK1 (0.47) | — | |
| SCHEMBL4474137 | 0.85 | DRD4 (0.55) | DRD4DRD3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21640417 | 0.85 | DRD4 (0.46) | DRD4DRD2DRD3ALDH1A1EPHX2 | |
| SCHEMBL6265631 | 0.85 | DRD4 (0.55) | DRD4DRD3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1502120 | 0.84 | DRD4 (0.59) | DRD4DRD2DRD3ALDH1A1EPHX2 | |
| SCHEMBL2770194 | 0.84 | DRD4 (0.61) | DRD4DRD2DRD3ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732460-B2 | Heterocyclic compounds, their preparation and their use as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | disclosed |
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | disclosed |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | TRPV4, TRPC4, TRPV1 | DRD4 398/4885DRD2 536/4885DRD3 497/4885 |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | MRPL21, NACA, NISCH | DRD4 1733/4885DRD2 2584/4885DRD3 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.